Mustang Bio, Inc. Share Price & Technical Analysis
MBIO · $0.63 (0.00%)
Healthcare / Biotechnology
$0.63
0.00%
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-25% return in May, 17% avg return in past 3 year May month.
-55% return in 2026, -88% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | 0% | -30% | 0% | -25% | – | – | – | – | – | – | – | -55% |
| 25 | -52% | -52% | -37% | -8% | 18% | -23% | 67% | 0% | 0% | 0% | -7% | -29% | -123% |
| 24 | 6% | -6% | -23% | -76% | -19% | 159% | -29% | -17% | -18% | 17% | -29% | -17% | -51% |
| 23 | 67% | -17% | -36% | -24% | 51% | -2% | -15% | -38% | -35% | -19% | -13% | -9% | -90% |
| 22 | -30% | -27% | 17% | -27% | -13% | -9% | -1% | 4% | -23% | 10% | -8% | -23% | -130% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children's hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$4.83M
P/E ratio
—
52W high
$7.00
52W low
$0.53
Volume
9,593
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Mustang Bio, Inc. share price today?
- Mustang Bio, Inc. (MBIO) last traded around $0.63 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does MBIO have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for MBIO. Download the app for real-time alerts.
- How can I analyze Mustang Bio, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.